Review : Current and new generation pneumococcal vaccines

dc.contributor.authorFeldman, Charles
dc.contributor.authorAnderson, Ronald
dc.contributor.emailronald.anderson@up.ac.zaen_US
dc.date.accessioned2014-11-07T12:06:32Z
dc.date.available2014-11-07T12:06:32Z
dc.date.issued2014-10
dc.description.abstractPneumococcal polysaccharide vaccines (PPVs) and conjugate vaccines (PCVs), of which PPV23 and PCV13 are the current front runners, have had a significant, beneficial impact on public health. With regard to PPV23, there has been some debate, however, about its protective efficacy against all-cause pneumonia, as opposed to invasive pneumococcal disease, in high-risk cases. PCVs, on the other hand, have been included in many national immunisation programmes for prevention of severe pneumococcal disease in infants and young children, as well as for adults in various high-risk categories. Although innovative and effective, the protective efficacy of PCVs, the composition of which is based on the geographic prevalence and virulence of pneumococcal serotypes, is limited due to colonisation of the nasopharynx with non-vaccine serotypes. This phenomenon of serotype replacement has provided the impetus for development of new generation recombinant protein and whole cell pneumococcal vaccines with the potential to provide serotype-independent protection. In addition to an overview of the successes and limitations of PPVs and PCVs, this review is focused on emerging and pipeline protein-based and whole cell vaccines, preceded by a consideration of conserved pneumococcal virulence factors which are potential vaccine candidates.en_US
dc.description.librarianhj2014en_US
dc.description.sponsorshipNational Research Foundation (SA)en_US
dc.description.urihttp://www.elsevierhealth.com/journals/jinfen_US
dc.identifier.citationFeldman, C & Anderson, R 2014, 'Review : Current and new generation pneumococcal vaccines', Journal of Infection, vol. 69, no. 4, pp. 309-325.en_US
dc.identifier.issn0163-4453 (print)
dc.identifier.issn1532-2742 (online)
dc.identifier.other10.1016/j.jinf.2014.06.006
dc.identifier.urihttp://hdl.handle.net/2263/42546
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2014 Published by Elsevier Ltd on behalf of The British Infection Association. Notice : this is the author’s version of a work that was accepted for publication in Journal of Infection. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Infection, vol. 69, no. 4, pp. 309-325, 2014. doi : 10.1016/j.jinf.2014.06.006.en_US
dc.subjectPneumococcal polysaccharide vaccines (PPVs)en_US
dc.subjectPneumococcal conjugate vaccines (PCVs)en_US
dc.subjectPneumococcal choline binding protein Aen_US
dc.subjectPneumococcal surface protein Aen_US
dc.subjectPneumococcal surface protein Cen_US
dc.subjectPneumolysinen_US
dc.subjectPolyhistidine triad proteinsen_US
dc.subjectRecombinant protein vaccinesen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectWhole cell vaccinesen_US
dc.titleReview : Current and new generation pneumococcal vaccinesen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Feldman_Review_2014.pdf
Size:
312.22 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: